Gamida Cell’s proprietary NAM technology is uniquely designed to provide a curative approach to treating a wide range of cancers and genetic diseases.
NAM technology is based on epigenetic regulation by the small molecule, Nicotinamide (NAM), and seeks to overcome challenges associated with expanding cells in a culture while preserving their characteristics and functionality, which typically decrease in culture conditions. This technology addresses these two limitations of ex vivo expansion by:
Gamida Cell has applied NAM technology to develop its lead clinical program by expanding blood forming stem and progenitor cells from umbilical cord blood to create highly functional, stand-alone grafts that serve as a universal bone marrow transplant solution.
Why use cord blood?
Given several limitations associated with bone marrow transplants, Gamida Cell developed its clinical assets using umbilical cord blood, a viable alternative graft source in which:
Current cord blood limitations: The use of standard cord blood for transplantation is limited because a unit of cord blood has a low number of stem and progenitor cells, resulting in delayed engraftment, a higher rate of graft failure, increased morbidity, prolonged hospitalization and higher transplant-related mortality.
Gamida Cell has successfully harnessed its NAM platform technology to leverage the advantages of cord blood and overcome its limitations by increasing the number of CD34+ stem and progenitor cells, while enhancing their homing and engraftment efficiency.
Gamida Cell has robust, cost-effective manufacturing capabilities, applying the proprietary NAM technology to create a large number of functional CD34+ cells for NiCord®.